Table 1.
Demographic details of study participants.
| Study A | Study B | |||||
|---|---|---|---|---|---|---|
| Control | Patient | p | Control | Patient | p | |
| N | 82 | 76 | 17 | 19 | ||
| Age, mean (SD) | 38.0 (12.2) | 35.4 (13.9) | 0.22 | 37.0 (8.9) | 39.7 (10.9) | 0.43 |
| Sex (% male) | 67% | 89% | 0.09 | 88% | 84% | 0.89 |
| PANSS Positive mean (SD) | NA | 16.4 (6.1) | NA | 18.5 (3.0) | ||
| PANSS Negative mean (SD) | NA | 16.5 (6.2) | NA | 19.6 (5.5) | ||
| PANSS General mean (SD) | NA | 30.3 (11.2) | NA | 34.4 (8.0) | ||
| PANSS Total mean (SD) | NA | 63.3 (19.9) | NA | 72.5 (10.2) | ||
| MATRICS overall | 50.0 (9.6) | 29.2 (13.3) | <0.001 | NA | NA | |
| Antipsychotic treated (%) | NA | 89% | NA | 100% | ||
| Antipsychotic dose (olanzapine equivalents/mg), mean (SD) | NA | 13.3 (12.9) | NA | 16.8 (9.8) | ||
MATRICS measurement and treatment research to improve cognition in schizophrenia, PANSS positive and negative syndrome scale.